الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 289 |  |  |
| | | from | 289 | | |
Abstract
Sepsis is one of the oldest and most elusive and most common medical syndromes. It is a serious, life-threatening clinical syndrome characterized by a robust and dysregulated immune response to a host to infection and is one of the leading causes of infection-related death. Sepsis is a complex, heterogeneous syndrome that includes physiological, pathological, and biochemical changes caused by infection. The current study aims to find novel and safe drug interventions that can protect against sepsis caused by bacterial infection and multiple organ dysfunction. The beneficial effects and potential protective mechanisms of saroglitazar, celesterol, and trimetazidine against acute liver, kidney, and lung tissue injuries caused by LPS were studied. Precautionary treatment of rats with the drugs under test for a period of 15 days before the injection of the endogenous toxin has led to the alleviation of blood poisoning and the accompanying defect in the functions of several organs such as the liver, kidneys and lungs (the organs under study) as evidenced by the improvement of liver function (decrease in liver enzymes). ) and kidney (low levels of creatinine and urea in the blood). Furthermore, the drugs were able to increase the organ’s overall antioxidant capacity (decreased MDA levels, increased superoxide dismutase activity, and reduced glutathione levels). The three drugs (Saroglitazar, Celastrol, and Trimetazidine) were able to reduce inflammation and the intense immune response against LPOs, which in turn leads to organ failure associated with septicemia, through a significant decrease in the levels of nuclear factor-kappa B, interferon-beta. , NLRP-3, interleukin-1 beta, caspase-1, caspase-11 and gasdermin D; which led to a reduction in the programmed death of immune cells associated with inflammation; This prevention also reduced the level of HMGB-1 in the liver, which in turn helps the entry of lipopolysaccharides into immune cells. This study revealed the promising effects of saroglitazar, celesterol, and trimetazidine in the prevention of LPS-induced sepsis and multi-organ dysfunction through their antioxidant and antiinflammatory effects, and their ability to protect against cell death and acute tissue injury. Finally, more comprehensive clinical studies are recommended to evaluate the efficacy of these drugs in alleviating the complications of septicemia and to characterize effective therapeutic doses.